Novel therapeutics for the treatment of metastatic melanoma

Future Oncology

Volumn 5, Issue 4, 2009, Pages 543-557

  Mansfield, Aaron S ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis inhibitors; Immunotherapy; Metastatic melanoma; Novel therapeutics; Tyrosine kinase inhibitors

Indexed keywords

AGATOLIMOD; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; FLUDARABINE; FOTEMUSTINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; IPILIMUMAB; MELANOMA VACCINE; PACLITAXEL; PEPTIDE VACCINE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RESIQUIMOD; TEMOZOLOMIDE; TICILIMUMAB; TOLL LIKE RECEPTOR AGONIST; TREOSULFAN; UNINDEXED DRUG; VINCRISTINE; CANCER VACCINE;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; LOW DRUG DOSE; MELANOMA; METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEA MELANOMA; IMMUNOTHERAPY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MELANOMA; RADIOTHERAPY; SKIN NEOPLASMS;

EID: 67651230913     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.15     Document Type: Review

References (152)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin. 58, 71-96 (2008).
2. Garbe C, Leiter U: Melanoma epidemiology and trends. Clin. Dermatol. 27, 3-9 (2009).
3. Bellett RE, Mastrangelo MJ, Laucius JF, Bodurtha AJ: Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma. Cancer Treat Rep. 60, 595-600 (1976).
4. Stevens MF, Hickman JA, Langdon SP et al.: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47, 5846-5852 (1987).
5. Middleton MR, Grob JJ, Aaronson N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18, 158-166 (2000).
6. Tsao H, Sober AJ: Melanoma treatment update. Dermatol. Clin. 23, 323-333 (2005).
7. Jacquillat C, Khayat D, Banzet P et al.: Final report of the French multicenter Phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66, 1873-1878 (1990).
8. Jacquillat C, Khayat D, Banzet P et al.: Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother. Pharmacol. 25, 263-266 (1990).
9. Avril MF, Aamdal S, Grob JJ et al.: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol. 22, 1118-1125 (2004).
10. Bedikian AY, Weiss GR, Legha SS et al.: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J. Clin. Oncol. 13, 2895-2899 (1995).
11. Einzig AI, Hochster H, Wiernik PH et al.: A Phase II study of taxol in patients with malignant melanoma. Invest. New Drugs 9, 59-64 (1991).
12. Einzig AI, Schuchter LM, Recio A et al.: Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med. Oncol. 13, 111-117 (1996).
13. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS: A Phase II trial of taxol in metastatic melanoma. Cancer 65, 2478-2481 (1990).
14. Wiernik PH, Schwartz EL, Einzig A et al.: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 5, 1232-1239 (1987).
15. Gradishar WJ, Tjulandin S, Davidson N et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005).
16. Nyman DW, Campbell KJ, Hersh E et al.: Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 23, 7785-7793 (2005).
17. Stinchcombe TE, Socinski MA, Walko CM et al.: Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother. Pharmacol. 60, 759-766 (2007).
18. Hersh E, O'Day S, Gonzalez R et al.: Multicenter Phase II study of ABI-007 (abraxane) in previously treated and chemotherapy naive patients with metastatic malignant melanoma (MMM). Abstract 27. Proceedings from the 23rd annual Chemotherapy Foundation Symposium 2005. New York, NY, USA, Abstract 27 (2005).
19. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol. 25, 283-286 (2002).
20. Zimpfer-Rechner C, Hofmann U, Figl R et al.: Randomized Phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 13, 531-536 (2003).
21. Rao RD, Holtan SG, Ingle JN et al.: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106, 375-382 (2006).
22. Corrie PG, Shaw J, Spanswick VJ et al.: Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br. J. Cancer 92, 1997-2003 (2005).
23. Schmittel A, Schuster R, Bechrakis NE et al.: A two-cohort Phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 15, 447-451 (2005).
24. Atzpodien J, Terfloth K, Fluck M, Reitz M: Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. Br. J. Cancer 97, 1329-1332 (2007).
25. Tas F, Camlica H, Topuz E: Temozolomide in combination with fotemustine in patients with metastatic melanoma. Cancer Chemother. Pharmacol. 62, 293-298 (2008).
26. McGovern VJ: Spontaneous regression of melanoma. Pathology 7, 91-99 (1975).
27. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am. J. Transplant 4, 905-913 (2004).
28. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ: Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl Acad. Sci. USA 73, 3278-3282 (1976).
29. Morton DL, Malmgren RA, Holmes EC, Ketcham AS: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64, 233-240 (1968).
30. Romsdahl MM, Cox IS: Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch. Surg. 100, 491-497 (1970).
31. Rosenberg SA, Yang JC, Topalian SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
32. Atkins MB, Lotze MT, Dutcher JP et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: ana lysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
33. Weinreich DM, Rosenberg SA: Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to α-interferon or low-dose interleukin-2. J. Immunother. 25, 185-187 (2002).
34. Weber JS, S O'Day, Urba W et al.: Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950-5956 (2008).
35. Attia P, Phan GQ, Maker AV et al.: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053 (2005).
36. Ribas A, Hauschild A, Kefford R et al.: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26, LBA9011 (2008) (Abstract).
37. Tarhini AA, Kirkwood JM: Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin. Biol. Ther. 8, 1583-1593 (2008).
38. Krieg AM, Yi AK, Matson S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995).
39. Pashenkov M, Goess G, Wagner C et al.: Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24, 5716-5724 (2006).
40. Hemmi H, Kaisho T, Takeuchi O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200 (2002).
41. Jurk M, Heil F, Vollmer J et al.: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3, 499 (2002).
42. Steinmann A, Funk JO, Schuler G, von den Driesch P: Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol. 43, 555-556 (2000).
43. Ray CM, Kluk M, Grin CM, Grant-Kels JM: Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int. J. Dermatol. 44, 428-434 (2005).
44. Conti L, Gessani S: GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 213, 859-870 (2008).
45. Dong Z, Yoneda J, Kumar R, Fidler IJ: Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188, 755-763 (1998).
46. Waller EK: The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 12(Suppl. 2), 22-26 (2007).
47. Spitler LE, Grossbard ML, Ernstoff MS et al.: Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18, 1614-1621 (2000).
48. Rao RD, Anderson PM, Arndt CA, Wettstein PJ, Markovic SN: Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am. J. Clin. Oncol. 26, 493-498 (2003).
49. Markovic SN, Suman VJ, Nevala WK et al.: A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am. J. Clin. Oncol. 31, 573-579 (2008).
50. Sato T, Eschelman DJ, Gonsalves CF et al.: Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 26, 5436-5442 (2008).
51. Dudley ME, Rosenberg SA: Adoptive cell transfer therapy. Semin. Oncol. 34, 524-531 (2007).
52. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA: Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 177, 6527-6539 (2006).
53. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24, 5060-5069 (2006).
54. Dudley ME, Wunderlich JR, Yang JC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251 (2002).
55. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
56. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346-2357 (2005).
57. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105, 241-250 (2005).
58. Shen X, Zhou J, Hathcock KS et al.: Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30, 123-129 (2007).
59. Zhou J, Shen X, Huang J et al.: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175, 7046-7052 (2005).
60. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
61. Dummer W, Niethammer AG, Baccala R et al.: T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110, 185-192 (2002).
62. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393 (2006).
63. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239 (2008).
64. Liu K, Rosenberg SA: Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J. Immunol. 167, 6356-6365 (2001).
65. Heemskerk B, Liu K, Dudley ME et al.: Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19, 496-510 (2008).
66. + T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008).
67. Terando AM, Faries MB, Morton DL: Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4-B16 (2007).
68. Vujanovic L, Butterfield LH: Melanoma cancer vaccines and anti-tumor T cell responses. J. Cell Biochem. 102, 301-310 (2007).
69. Roberts JD, Niedzwiecki D, Carson WE et al.: Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J. Immunother. 29, 95-101 (2006).
70. Hsueh EC, Essner R, Foshag LJ et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 20, 4549-4554 (2002).
71. Nestle FO, Alijagic S, Gilliet M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
72. Schadendorf D, Ugurel S, Schuler-Thurner B et al.: Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17, 563-570 (2006).
73. Grover A, Kim GJ, Lizee G et al.: Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin. Cancer Res. 12, 5801-5808 (2006).
74. Lindsey KR, Gritz L, Sherry R et al.: Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. Clin. Cancer Res. 12, 2526-2537 (2006).
75. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746 (2005).
76. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
77. Smith FO, Downey SG, Klapper JA et al.: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14, 5610-5618 (2008).
78. Streit M, Detmar M: Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22, 3172-3179 (2003).
79. Kurzen H, Schmitt S, Naher H, Mohler T: Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14, 515-522 (2003).
80. Lacal PM, Failla CM, Pagani E et al.: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J. Invest. Dermatol. 115, 1000-1007 (2000).
81. Lev DC, Onn A, Melinkova VO et al.: Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J. Clin. Oncol. 22, 2092-2100 (2004).
82. Lev DC, Ruiz M, Mills L et al.: Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther. 2, 753-763 (2003).
83. Vihinen PP, Hilli J, Vuoristo MS, Syrjanen KJ, Kahari VM, Pyrhonen SO: Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol. 46, 678-684 (2007).
84. Graham CH, Rivers J, Kerbel RS, Stankiewicz KS, White WL: Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am. J. Pathol. 145, 510-514 (1994).
85. Lane AM, Egan KM, Yang J et al.: An evaluation of tumour vascularity as a prognostic indicator in uveal melanoma. Melanoma Res. 7, 237-242 (1997).
86. Massi D, Franchi A, Borgognoni L et al.: Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic ana lysis. Virchows Arch. 440, 22-28 (2002).
87. Massi D, Franchi A, Paglierani M et al.: Vasculogenic mimicry has no prognostic significance in pT3 and pT4 cutaneous melanoma. Hum. Pathol. 35, 496-502 (2004).
88. Tas F, Duranyildiz D, Oguz H et al.: Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res. 16, 405-411 (2006).
89. Ugurel S, Rappl G, Tilgen W, Reinhold U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577-583 (2001).
90. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
91. Motzer RJ, Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24, 5601-5608 (2006).
92. Hwu WJ, Panageas KS, Menell JH et al.: Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma. Cancer 106, 2445-2451 (2006).
93. Hwu WJ, Lis E, Menell JH et al.: Temozolomide plus thalidomide in patients with brain metastases from melanoma: a Phase II study. Cancer 103, 2590-2597 (2005).
94. Pawlak WZ, Legha SS: Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res. 14, 57-62 (2004).
95. Reiriz AB, Richter MF, Fernandes S et al.: Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res. 14, 527-531 (2004).
96. Weng DE, Masci PA, Radka SF et al.: A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. 4, 948-955 (2005).
97. Dinney CP, Bielenberg DR, Perrotte P et al.: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58, 808-814 (1998).
98. Sangfelt O, Erickson S, Castro J et al.: Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18, 2798-2810 (1999).
99. Varker KA, Biber JE, Kefauver C et al.: A randomized Phase 2 trial of bevacizumab with or without daily low-dose interferon α-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14, 2367-2376 (2007).
100. Solti M, Berd D, Mastrangelo MJ, Sato T: A pilot study of low-dose thalidomide and interferon α-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res. 17, 225-231 (2007).
101. Markovic SN, Suman VJ, Rao RA et al.: A Phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am. J. Clin. Oncol. 30, 303-309 (2007).
102. Perez DG, Suman VJ, Fitch TR et al.: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage Imelanoma V: a North Central cancer treatment group study, N047A. Cancer 115, 119-127 (2009).
103. Beadling C, E Jacobson-Dunlop, Hodi FS et al.: KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. 14, 6821-6828 (2008).
104. Jiang X, Zhou J, Yuen NK et al.: Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. 14, 7726-7732 (2008).
105. Hodi FS, Friedlander P, Corless CL et al.: Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26, 2046-2051 (2008).
106. Wyman K, Atkins MB, Prieto V et al.: Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106, 2005-2011 (2006).
107. Kim KB, Eton O, Davis DW et al.: Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 99, 734-740 (2008).
108. Wilhelm SM, Carter C, Tang L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
109. Escudier B, Lassau N, Angevin E et al.: Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 13, 1801-1809 (2007).
110. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
111. Eisen T, Ahmad T, Flaherty KT et al.: Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial ana lysis. Br. J. Cancer 95, 581-586 (2006).
112. Kirshner JR, He S, Balasubramanyam V et al.: Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 7, 2319-2327 (2008).
113. Foley K, Bertin J, Chan K et al.: The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models [abstract]. In: Program and proceedings of the AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics: discovery, biology, and clinical applications; Oct 22-26, 2007; San Francisco, CA. AACR 159, A290 (2007) (Abstract).
114. Berkenblit A, Eder JP Jr, Ryan DP et al.: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin. Cancer Res. 13, 584-590 (2007).
115. Lawson D, Gonzalez R, Weber W et al.: 2-year overall survival (OS) results of a Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). J. Clin. Oncol. 26, abstr 20023 (2008).
116. Bajetta E, A Di Leo, Zampino MG et al.: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon α-2a in the treatment of advanced melanoma. J. Clin. Oncol. 12, 806-811 (1994).
117. Johnston SR, Constenla DO, Moore J et al.: Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon α (IFN-α) and interleukin (IL-2) in patients with metastatic melanoma. Br. J. Cancer 77, 1280-1286 (1998).
118. Kirkwood JM, Ernstoff MS, Giuliano A et al.: Interferon α-2a and dacarbazine in melanoma. J. Natl Cancer Inst. 82, 1062-1063 (1990).
119. Keilholz U, Goey SH, Punt CJ et al.: Interferon α-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European organization for research and treatment of cancer melanoma cooperative group. J. Clin. Oncol. 15, 2579-2588 (1997).
120. Ives NJ, Stowe RL, Lorigan P, Wheatley K: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J. Clin. Oncol. 25, 5426-5434 (2007).
121. Garcia M, XG del Muro, Tres A et al.: Phase II multicentre study of temozolomide in combination with interferon α-2b in metastatic malignant melanoma. Melanoma Res. 16, 365-370 (2006).
122. Richtig E, R Hofmann-Wellenhof, Pehamberger H et al.: Temozolomide and interferon α 2b in metastatic melanoma stage IV. Br. J. Dermatol. 151, 91-98 (2004).
123. Atkins MB, Hsu J, Lee S et al.: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern cooperative oncology group. J. Clin. Oncol. 26, 5748-5754 (2008).
124. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS: A Phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer 113, 1632-1640 (2008).
125. Flaherty KT, Schiller J, Schuchter LM et al.: A Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 14, 4836-4842 (2008).
126. Agarwala S, Keilholz U, Hogg D et al.: Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol. 25(18S), 8510 (2007) (Abstract).
127. McDermott D, Sosman J, Hodi F et al.: Randomized Phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma. J. Clin. Oncol. 25(18S), 8511 (2007) (Abstract).
128. Jansen B, Schlagbauer-Wadl H, Brown BD et al.: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4, 232-234 (1998).
129. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12, 193-213 (2002).
130. Schmitt CA, Rosenthal CT, Lowe SW: Genetic ana lysis of chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029-1035 (2000).
131. Bedikian AY, Millward M, Pehamberger H et al.: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen melanoma study group. J. Clin. Oncol. 24, 4738-4745 (2006).
132. Diener-West M, Earle JD, Fine SL et al.: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch. Ophthalmol. 119, 969-982 (2001).
133. Harwood AR, Lawson VG: Radiation therapy for melanomas of the head and neck. Head Neck Surg. 4, 468-474 (1982).
134. Ang KK, Byers RM, Peters LJ et al.: Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results. Arch. Otolaryngol. Head Neck Surg. 116, 169-172 (1990).
135. Overgaard J, H von der Maase, Overgaard M: A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 11, 1837-1839 (1985).
136. Olivier KR, Schild SE, Morris CG, Brown PD, Markovic SN: A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110, 1791-1795 (2007).
137. Beadle BM, Guadagnolo BA, Ballo MT et al.: Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int. J. Radiat. Oncol. Biol. Phys. 73(5), 1376-1382 (2009).
138. Brown PD, Brown CA, Pollock BE, Gorman DA, Foote RL: Stereotactic radiosurgery for patients with 'radioresistant' brain metastases. Neurosurgery 62(Suppl. 2), 790-801 (2008).
139. McWilliams RR, Rao RD, Buckner JC et al.: Melanoma-induced brain metastases. Expert Rev. Anticancer Ther. 8, 743-755 (2008).
140. Allen PJ, Coit DG: The role of surgery for patients with metastatic melanoma. Curr. Opin. Oncol. 14, 221-226 (2002).
141. Allen PJ, Coit DG: The surgical management of metastatic melanoma. Ann. Surg. Oncol. 9, 762-770 (2002).
142. Wong SL, Coit DG: Role of surgery in patients with stage IV melanoma. Curr. Opin. Oncol. 16, 155-160 (2004).
143. Young SE, Martinez SR, Essner R: The role of surgery in treatment of stage IV melanoma. J. Surg. Oncol. 94, 344-351 (2006).
144. Meier F, Will S, Ellwanger U et al.: Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol. 147, 62-70 (2002).
145. Leo F, Cagini L, Rocmans P et al.: Lung metastases from melanoma: when is surgical treatment warranted? Br. J. Cancer 83, 569-572 (2000).
146. Meyer T, Merkel S, Goehl J, Hohenberger W: Surgical therapy for distant metastases of malignant melanoma. Cancer 89, 1983-1991 (2000).
147. Morton DL, Ollila DW, Hsueh EC, Essner R, Gupta RK: Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J. Clin. 49, 101-116, 65 (1999).
148. Rose DM, Essner R, Hughes TM et al.: Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch. Surg. 136, 950-955 (2001).
149. Wood TF, DiFronzo LA, Rose DM et al.: Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann. Surg. Oncol. 8, 658-662 (2001).
150. Ollila DW, Hsueh EC, Stern SL, Morton DL: Metastasectomy for recurrent stage IV melanoma. J. Surg. Oncol. 71, 209-213 (1999).
151. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS: Survival ana lysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer 106, 1353-1357 (2006).
152. Tauceri F, Mura G, Roseano M, Framarini M, Ridolfi L, Verdecchia GM: Surgery and adjuvant therapies in the treatment of stage IV melanoma: our experience in 84 patients. Langenbecks Arch. Surg. (2008) (Epub ahead of print).